drugset
drugset / Trial / NCT03316482

Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty

NCT03316482 ↗

Phase 4 Completed 58 enrolled Jin Soon Hwang
NaSingle-groupOpen-labelTreatment

Summary

A multicenter, open-label, prospective study to evaluate the safety and efficacy of leuprorelin acetate DPS (Leuplin DPS) treatment quarterly in patients with central precocious puberty

Timeline

Start
2015-06-11
Primary completion
2019-08-29
Completion
2019-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Leuprolide Other / unclassified 11.25 mg Subcutaneous

Indications

central precocious puberty